✨ Your Portfolio is fetched and updated from zerodha.
Small Pharmaceuticals
Market Cap
₹13,760 Cr.
P/E
22.42

Key Ratios

Market cap
Market cap
13,760 Cr
PE
PE
22.42
Prom Holding
Prom Holding
70.57 %
ROE (%)
ROE (%)
18.81
ROCE (%)
ROCE (%)
23.36
Div Yield (%)
Div Yield (%)
0.33
Sales
Sales
2,089 Cr
OPM (%)
OPM (%)
34.68 %
Debt to Equity
Debt to Equity
0.00
Institutions
Institutions
8.29 %
Individual < 2 lac
Individual < 2 lac
12.17 %
No. of Shareholders
No. of Shareholders
93,896

About

Caplin Point Laboratories was established in 1990 to manufacture a range of ointments, creams … Read more
Low
1502
52W Range
High
2397
  • Caplin Point Lab
  • Gufic Biosciences
  • Gland Pharma
  • TJI Pharma - Small Cap

Timeline

Dividend Update Board Meeting Financials

Key company specific updates

Custom financial statement

New
Edit rows

Forensics

9 Yes

Positive for this company

3 Neutral

Neutral for this company

5 No

Negative for this company

0 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Distribution Channel

Manufacturing Break-Up

Operational Metrics

    Select a Metric
    • Number of ANDA's Filed in USA (.)
    • Number of ANDA's Approved By USFDA (.)
    • R&D as a % of Total Sales (%)

    Peer Comparison

    Corporate Actions

    Consolidated
    DATE
    DETAILS
    Show More
    Show Less
    Show More
    Show Less

    FAQs on Caplin Point Laboratories Ltd. Business

    Established in 1990, Caplin Point Laboratories is a mid-sized company in India manufacturing APIs, finished formulations, and engaging in research & development, clinical research, and global marketing.

    Caplin Point Lab major competitors are Gufic Biosciences, Gland Pharma, Alembic Pharma, Jubilant Pharmova, Strides Pharma Scien, Viyash Scientific, Marksans Pharma.
    Market Cap of Caplin Point Lab is ₹13,979 Crs.
    While the median market cap of its peers are ₹10,561 Crs.

    Caplin Point Lab seems to be financially stable compared to its competitors.
    The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

    Company Filing

    Discussions & Analysis

    Ideas Dashboard
    Results
    Timeline
    Watchlist
    Portfolio
    Alerts
    Stock Screener
    Market
    Raw Material